|Dr. Shai N. Gozani M.D., Ph.D.||Founder, Chairman, Chief Exec. Officer, Pres and Sec.||415k||N/A||52|
|Mr. Thomas T. Higgins||Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer||325k||N/A||65|
|Mr. Francis X. McGillin||Chief Commercial Officer and Sr. VP||325k||N/A||56|
|Mr. Michael J. MacDonald||Sr. VP of Commercial Operations||N/A||N/A||N/A|
|Dr. Xuan Kong Ph.D.||Sr. VP of Research & Intellectual Property||N/A||N/A||N/A|
NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; the SENSUS pain therapy device, a prescription neurostimulation device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies. The company offers its products to consumers, patients, retail merchandisers, health care professionals, durable medical equipment suppliers, physicians, clinics, hospitals, managed care organizations, independent distributors, retail health businesses, endocrinologists, podiatrists, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neuro surgeons primarily in the United States, Europe, Asia, the Middle East, and internationally. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.
NeuroMetrix, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.